Abstract: Provided is a traditional Chinese herbal composition for treating pulmonary nodules, a preparation method thereof, and a honeyed pill. The composition comprises: 30 parts by weight of Ziziphi Spinosae Semen, 20-30 parts by weight of Rehmaniae Radix, 30 parts by weight of Trichosanthis Radix, 40-50 parts by weight of Paeoniae Radix Alba, 30 parts by weight of Coicis Semen Preparata, 20 parts by weight of Ginseng Radix et Rhizoma, 10 parts by weight of Olibanum, 10 parts by weight of Myrrha, 20-30 parts by weight of Testudinis Carapax et Plastrum Preparata Cum Aceto, 20-30 parts by weight of Trionycis Carapax Preparata Cum Aceto, 30 parts by weight ofAgrimoniae Herba, 10-20 parts by weight ofAlpiniae Oxyphyllae Fructus, 5 parts by weight of Toosendan Fructus, 20 parts by weight of Poria, 10 parts by weight of Platycodonis Radix, and 10 parts by weight of Polygalae Radix.

Abstract: A method and a device for securing a cache against side channel attacks are provided. An allocator identifier ALLOCATOR field is added to each cache entry in the present disclosure. Whenever an entry is allocated in the cache, the identifier of the software domain currently running on the processor is filled into the ALLOCATOR field of the allocation entry. When accessing the cache, the cache entry can be hit only if the identifier of the software domain currently running on the processor is identical to the ALLOCATOR field in the cache entry. If the cache entry to be replaced is invalid or its ALLOCATOR field is identical to the identifier of the software domain currently running on the processor, then the existing entry in the cache is replaced directly; otherwise, the entire cache is emptied.

Abstract: A method and a device for securing a cache against side channel attacks are provided. An allocator identifier ALLOCATOR field is added to each cache entry in the present disclosure. Whenever an entry is allocated in the cache, the identifier of the software domain currently running on the processor is filled into the ALLOCATOR field of the allocation entry. When accessing the cache, the cache entry can be hit only if the identifier of the software domain currently running on the processor is identical to the ALLOCATOR field in the cache entry. If the cache entry to be replaced is invalid or its ALLOCATOR field is identical to the identifier of the software domain currently running on the processor, then the existing entry in the cache is replaced directly; otherwise, the entire cache is emptied.

Abstract: The present invention relates to a mutant G-CSF fusion protein. The mutant G-CSF fusion protein is a fusion protein having the activity of stimulating the proliferation of neutrophilic granulocytes, and having a basic structure of G-CSF/carrier protein or carrier protein/G-CSF; wherein the G-CSF moiety comprises multipoint substitutions thus resulting in changes in biological activity and binding affinity. Compared with existing products, the mutant G-CSF fusion protein in the present invention has longer half-life and higher biological activity. Administration of the pharmaceutical preparation containing this mutant G-CSF fusion protein could be used in the treating neutropenia.

Abstract: The present invention relates to an arginine deiminase mutant with partial lysine-deficient and preparation and application thereof. The arginine deiminase mutant of the present invention has enzymatic activity of degrading arginine into citruline; compared with the arginine deiminase with the amino acid sequence of SEQ ID NO: 1, the amino acid sequence comprises one or more of K9N, T, K59Q, K66R, A, K93E, A, Q, K111R, A, K119Q, L, M, K121Q, I, K122E, L, K126E, S, R, K178I, E, D, K196I, R, K209G, T, D, K243E, V, R, K249D, Q, K263N, Q, K279Y, T, K293R, H, E, K325V, I, K380T, R, E, and K406E, D, S substitutions. Compared with PEG modified natural derived arginine deiminase, the PEG modified arginine deiminase mutant of the present invention retain better bioactivity; and because the quantity of lysine in arginine deiminase is reduced, the PEG modified products are more uniform and can be applied to clinical treatment of hepatoma, melanoma and the like.

Abstract: The present invention relates to a mutant G-CSF fusion protein. The mutant G-CSF fusion protein is a fusion protein having the activity of stimulating the proliferation of neutrophilic granulocytes, and having a basic structure of G-CSF/carrier protein or carrier protein/G-CSF; wherein the G-CSF moiety comprises multipoint substitutions thus resulting in changes in biological activity and binding affinity. Compared with existing products, the mutant G-CSF fusion protein in the present invention has longer half-life and higher biological activity. Administration of the pharmaceutical preparation containing this mutant G-CSF fusion protein could be used in the treating neutropenia.

Abstract: The present invention relates to an arginine deiminase mutant with partial lysine-deficient and preparation and application thereof. The arginine deiminase mutant of the present invention has enzymatic activity of degrading arginine into citruline; compared with the arginine deiminase with the amino acid sequence of SEQ ID NO: 1, the amino acid sequence comprises one or more of K9N, T, K59Q, K66R, A, K93E, A, Q, K111R, A, K119Q, L, M, K121Q, I, K122E, L, K126E, S, R, K178I, E, D, K196I, R, K209G, T, D, K243E, V, R, K249D, Q, K263N, Q, K279Y, T, K293R, H, E, K325V, I, K380T, R, E, and K406E, D, S substitutions. Compared with PEG modified natural derived arginine deiminase, the PEG modified arginine deiminase mutant of the present invention retain better bioactivity; and because the quantity of lysine in arginine deiminase is reduced, the PEG modified products are more uniform and can be applied to clinical treatment of hepatoma, melanoma and the like.